These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12856804)

  • 1. Lumbar bone mineral density in prostate cancer patients with bone metastases.
    Chang CH; Tsai CS; Jim YF; Wu HC; Lin CC; Kao A
    Endocr Res; 2003 May; 29(2):177-82. PubMed ID: 12856804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is bone mineral density measurement using dual-energy X-ray absorptiometry affected by gamma rays?
    Xie LJ; Li JF; Zeng FW; Jiang H; Cheng MH; Chen Y
    J Clin Densitom; 2013; 16(3):275-278. PubMed ID: 23473956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification evaluation of
    Huang K; Feng Y; Liu D; Liang W; Li L
    Ann Nucl Med; 2020 Feb; 34(2):136-143. PubMed ID: 31768820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between BMD and bone scintigraphy in patients with prostate cancer.
    Perk H; Yildiz M; Kosar A; Cerci S; Soyupek F; Ozorak A; Dilmen C
    Urol Oncol; 2008; 26(3):250-3. PubMed ID: 18452814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antecedent 99mTc-MDP and 99mTc-sestamibi administration corrupts bone mineral density measured by DXA.
    McKiernan FE; Hocking J; Cournoyer S
    J Clin Densitom; 2006; 9(2):164-6. PubMed ID: 16785076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of 99mTc-MIBI and 99mTc-MDP administration on dual-energy X-ray absorptiometry bone mineral density measurements.
    Gumuser G; Parlak Y; Topal G; Aras F; Ruksen E; Sayit E
    Nucl Med Commun; 2009 Jun; 30(6):445-8. PubMed ID: 19357550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
    Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
    Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bone mineral density change: comparison between prostate cancer patients with or without metastases and healthy men (a North African ethnic group)].
    Janane A; Hajji F; Ismail T; Jawad C; Crepin-Elondo J; Ghadouane M; Ameur A; Abbar M; Albouzidi A
    Actas Urol Esp; 2011; 35(7):414-9. PubMed ID: 21550141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disappearance of 99mTc-MDP accumulation in metastatic bone disease during bone scintigraphy.
    Kinoshita T; Ishii K; Imai Y
    Radiat Med; 1997; 15(4):235-7. PubMed ID: 9311040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between 99Tcm-MDP uptake and bone mineral density in patients with prostatic carcinoma.
    Sundkvist GM; Nilsson M; Ahlgren L; Lilja B; Mattsson S; Birch-Iensen M; Abrahamsson PA
    Nucl Med Commun; 1991 Jul; 12(7):629-36. PubMed ID: 1923154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidental detection of skeletal metastases on technetium-99m DTPA renal scintigraphy.
    Prakash R
    Australas Radiol; 1995 May; 39(2):182-4. PubMed ID: 7605328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study on the distribution features of bone metastases in prostate cancer.
    Wang C; Shen Y
    Nucl Med Commun; 2012 Apr; 33(4):379-83. PubMed ID: 22293499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of bone scintigraphy and 18F-FDG PET-CT in a prostate cancer patient with osteolytic bone metastases.
    Ozcan Kara P; Kara T; Kara Gedik G; Sari O; Sahin O
    Rev Esp Med Nucl; 2011; 30(2):94-6. PubMed ID: 21342722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibular findings in carcinoma prostate; a challenging situation for reporting physician.
    Rashid N; Javed MM; Hassan A
    J Pak Med Assoc; 2019 Oct; 69(10):1572-1573. PubMed ID: 31622322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone mineral density and bone scintigraphy in adult Saudi female patients with osteomalacia.
    El-Desouki MI; Othman SM; Fouda MA
    Saudi Med J; 2004 Mar; 25(3):355-8. PubMed ID: 15048176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone mineral density for patients with bone metastasis of prostate cancer: a preliminary report.
    Tanaka H; Furukawa Y; Fukunaga K; Fukunaga M
    Adv Exp Med Biol; 1992; 324():217-31. PubMed ID: 1492619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormalities in bone mineral density distribution and bone scintigraphy in patients with childhood onset hypopituitarism.
    Kosowicz J; El Ali Z; Ziemnicka K; Sowinski J
    J Clin Densitom; 2007; 10(3):332-9. PubMed ID: 17470407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of the Usefulness of Bone Scan Index Calculated From 99m-Technetium- Hydroxymethylene Diphosphonate (
    Higashiyama S; Yoshida A; Kawabe J
    Curr Med Imaging; 2021; 17(1):89-96. PubMed ID: 32484112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maximum standardized uptake value from quantitative bone single-photon emission computed tomography/computed tomography in differentiating metastatic and degenerative joint disease of the spine in prostate cancer patients.
    Mohd Rohani MF; Mat Nawi N; Shamim SE; Wan Sohaimi WF; Wan Zainon WMN; Musarudin M; Said MA; Hashim H
    Ann Nucl Med; 2020 Jan; 34(1):39-48. PubMed ID: 31612417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.